14.8 C
New York
Friday, April 26, 2024
HomeMarkets
Markets

Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

By Insider Scoop
0
21
psw-placeholder
psw-placeholder

Courtesy of Benzinga.

Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

  • Leerink recently hosted 24 biopharmaceutical companies at a roundtable event.
  • Of the 24 companies, Leerink now rates 20 of them as Outperform.
  • Many of these 20 companies have strong potential catalysts coming relatively soon.

    • Leerink Partners recently hosted a Rare Disease Roundtable that included fireside chats with 24 biopharmaceutical companies. Following the event, analyst Joseph Schwartz released a report that included a list of 20 Outperform-rated names that attended the roundtable.

    Here’s a list of some of the potential catalysts Schwartz sees for these companies.

    Highlighted Stocks And Catalysts

  • Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR): The company is guiding conservatively for Juxtapid sales.
  • Agios Pharmaceuticals Inc (NASDAQ: AGIO): The company is seeing clinical benefit in solid tumor indications.
  • Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY): The company reports solid enrollment in APOLLO Ph. III trial and positive OLE Phase II data.

    • Related Link: Morgan Stanley Sees Drug Pricing Still An Overhang For These Names

  • Ascendis Pharma A/S (NASDAQ: ASND): The company is ramping up manufacturing ahead of Ph. III trial in growth deficiency patients.
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN): The company has a scheduled PDUFA date of December 27.
  • Cidara Therapeutics Inc (NASDAQ: CDTX): The company is executing well on CD101 development.
  • Dicerna Pharmaceuticals Inc (NASDAQ: DRNA): A decision on the fate of DCR-MYC is expected by the end of 2016.

    • Other Names

    In addition to the specific names mentioned above, Leerink also sees potential upcoming catalysts for the following Outperform-rated names in the space:

    • Auris Medical Holding AG (NASDAQ: EARS)
    • Epizyme Inc (NASDAQ: EPZM)
    • Fate Therapeutics Inc (NASDAQ: FATE)
    • Amicus Therapeutics, Inc. (NASDAQ: FOLD)
    • Insmed Incorporated (NASDAQ: INSM)
    • ProQR Therapeutics NV (NASDAQ: PRQR)
    • Uniqure NV (NASDAQ: QURE)
    • Raptor Pharmaceutical Corp. (NASDAQ: RPTP)
    • Retrophin Inc (NASDAQ: RTRX)
    • SAGE Therapeutics Inc (NASDAQ: SAGE)
    • Acceleron Pharma Inc (NASDAQ: XLRN)
    • Zafgen Inc (NASDAQ: ZFGN)
    • Zogenix, Inc. (NASDAQ: ZGNX)

    Disclosure: The author holds no position in the stocks mentioned.

    Image Credit: Public Domain

    Posted-In: BiopharmaceuticalAnalyst Color Biotech Long Ideas Top Stories Analyst Ratings Trading Ideas General Best of Benzinga

    Subscribe
    Notify of
    0 Comments
    Inline Feedbacks
    View all comments

    Stay Connected

    157,318FansLike
    396,312FollowersFollow
    2,290SubscribersSubscribe

    Latest Articles

    Load more

    Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.

    This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

    Contact us: support@philstockworld.com

    © Copyright - PSW, LLC.

    2024
    0
    Would love your thoughts, please comment.x
    ()
    x